Arrowhead Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended June 30, 2023. For the third quarter, the company reported sales was USD 15.83 million compared to USD 32.41 million a year ago. Net loss was USD 102.95 million compared to USD 72.05 million a year ago. Basic loss per share from continuing operations was USD 0.96 compared to USD 0.68 a year ago. Diluted loss per share from continuing operations was USD 0.96 compared to USD 0.68 a year ago.
For the nine months, sales was USD 224.64 million compared to USD 211.66 million a year ago. Net loss was USD 95.6 million compared to USD 90.55 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 0.86 a year ago. Diluted loss per share from continuing operations was USD 0.9 compared to USD 0.86 a year ago.